546 related articles for article (PubMed ID: 18462850)
21. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components.
Hahn UK; Boehm R; Beyer W
Vaccine; 2006 May; 24(21):4569-71. PubMed ID: 16157424
[TBL] [Abstract][Full Text] [Related]
22. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.
Herrmann JE; Wang S; Zhang C; Panchal RG; Bavari S; Lyons CR; Lovchik JA; Golding B; Shiloach J; Lu S
Vaccine; 2006 Jul; 24(31-32):5872-80. PubMed ID: 16790303
[TBL] [Abstract][Full Text] [Related]
23. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
[TBL] [Abstract][Full Text] [Related]
24. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.
Fasanella A; Tonello F; Garofolo G; Muraro L; Carattoli A; Adone R; Montecucco C
Vaccine; 2008 Oct; 26(45):5684-8. PubMed ID: 18775462
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of a subunit vaccine against Bacillus anthracis.
Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
[TBL] [Abstract][Full Text] [Related]
26. [Progress on the vaccine for anthrax].
Zhan DW; Wang P; Wang LC; Zhang ZS
Wei Sheng Wu Xue Bao; 2005 Feb; 45(1):149-52. PubMed ID: 15847185
[TBL] [Abstract][Full Text] [Related]
27. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
Gupta M; Alam S; Bhatnagar R
Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
29. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
[TBL] [Abstract][Full Text] [Related]
30. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
[TBL] [Abstract][Full Text] [Related]
32. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
Park YS; Lee JH; Hung CF; Wu TC; Kim TW
Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
[TBL] [Abstract][Full Text] [Related]
34. Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine.
Gorantala J; Grover S; Rahi A; Chaudhary P; Rajwanshi R; Sarin NB; Bhatnagar R
J Biotechnol; 2014 Apr; 176():1-10. PubMed ID: 24548460
[TBL] [Abstract][Full Text] [Related]
35. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
Li H; Soroka SD; Taylor TH; Stamey KL; Stinson KW; Freeman AE; Abramson DR; Desai R; Cronin LX; Oxford JW; Caba J; Pleatman C; Pathak S; Schmidt DS; Semenova VA; Martin SK; Wilkins PP; Quinn CP
J Immunol Methods; 2008 Apr; 333(1-2):89-106. PubMed ID: 18304568
[TBL] [Abstract][Full Text] [Related]
36. Anthrax capsule vaccine protects against experimental infection.
Chabot DJ; Scorpio A; Tobery SA; Little SF; Norris SL; Friedlander AM
Vaccine; 2004 Nov; 23(1):43-7. PubMed ID: 15519706
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccines for biodefense.
Dupuy LC; Schmaljohn CS
Expert Rev Vaccines; 2009 Dec; 8(12):1739-54. PubMed ID: 19943766
[TBL] [Abstract][Full Text] [Related]
38. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
[TBL] [Abstract][Full Text] [Related]
39. Protein- and DNA-based anthrax toxin vaccines confer protection in guinea pigs against inhalational challenge with Bacillus cereus G9241.
Palmer J; Bell M; Darko C; Barnewall R; Keane-Myers A
Pathog Dis; 2014 Nov; 72(2):138-42. PubMed ID: 25044336
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the human immune response to the UK anthrax vaccine.
Baillie L; Townend T; Walker N; Eriksson U; Williamson D
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
